2 results
Approved WMOPending
The purpose of this study is to show that the incidence of new thrombotic events during an additional 6 or 12 months of treatment with rivaroxaban is lower when compared to placebo and that the likely advantage of an extended effect is not offset by…
Approved WMOPending
To investigate whether COX-2 inhibition enhances platelet aggregation by suppression of prostacyclin formation without suppressing thromboxane formation